Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ixabepilone

FDA-approved product (injectable, intravenous), marketed as Ixempra Kit.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Ixabepilone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Breast carcinoma
  • Breast neoplasm
  • Cancer
  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other cytotoxic antibiotics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA54.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis38.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ixabepilone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-5.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-5.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-5.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ixabepilone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • BMS-247550 in Treating Patients With Advanced Pancreatic Cancer

    NCT00016965 · start 2001-07

    Registered record
    Registry ID
    NCT00016965
    Conditions
    Pancreatic Cancer
    Interventions
    ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-07
    Completion
    2006-04
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Cancer
    Interventionixabepilone
    PhasePhase 2
    Registry statusCompleted

  • Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer

    NCT00025194 · start 2001-07

    Registered record
    Registry ID
    NCT00025194
    Conditions
    Prostate Cancer
    Interventions
    estramustine phosphate sodium; ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2001-07
    Completion
    2006-07
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstate Cancer
    Interventionestramustine phosphate sodium; ixabepilone
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • A Phase II Study of Epothilone Analog BMS-247550 in Patients With Non-Small Cell Lung Cancer Who Have Failed First Line Platinum Based Chemotherapy

    NCT00035516 · start 2001-02

    Registered record
    Registry ID
    NCT00035516
    Conditions
    Carcinoma, Non-small-cell Lung
    Interventions
    Epothilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-02
    Completion
    2004-04
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarcinoma, Non-small-cell Lung
    InterventionEpothilone
    PhasePhase 2
    Registry statusCompleted

  • BMS-247550 in Treating Patients With Advanced Cancers

    NCT00006221 · start 2000-11

    Registered record
    Registry ID
    NCT00006221
    Conditions
    Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    ixabepilone
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2000-11
    Completion
    Not recorded
    Enrolment
    54

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventionixabepilone
    PhasePhase 1
    Registry statusCompleted

  • Treating Patients With Advanced Solid Tumors, Breast Cancer or Recurrent Ovarian Cancer

    NCT00005807 · start 2000-07

    Registered record
    Registry ID
    NCT00005807
    Conditions
    Breast Cancer; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    Interventions
    BMS-247550
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2000-07
    Completion
    2004-08
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer; Ovarian Cancer; Unspecified Adult Solid Tumor, Protocol Specific
    InterventionBMS-247550
    PhasePhase 1
    Registry statusCompleted